+1 877 705 191424 / 7
HIPAA Compliant
ISO 27001 Certified

Completed

Phase 3
Age: 21Years +
All Genders
ID00000131

Central Vein Occlusion Study (CVOS)

Led by National Eye Institute (NEI) · Updated on 2009-09-17

N/A

Participants Needed

N/A

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

To determine whether photocoagulation therapy can help prevent iris neovascularization in eyes with central vein occlusion (CVO) and evidence of ischemic retina. To assess whether grid-pattern photocoagulation therapy will reduce loss of central visual acuity due to macular edema secondary to CVO. To develop new data describing the course and prognosis for eyes with CVO.

CONDITIONS

Brief Title

Central Vein Occlusion Study (CVOS)

Who Can Participate

Age: 21Years +
All Genders

Eligibility Criteria

Men and women must have been age 21 or older and willing to return for followup visits for 3 years following assignment into the appropriate group and randomization. Each of the four groups has specific eligibility criteria. Patients with retinal vascular disease other than that specified in the criteria, such as diabetic retinopathy, were ineligible. Patients with macular disease other than that due to CVO were ineligible for that portion of the study.

Trial Site Locations

Site Locations not provided

Location information for this trial is currently unavailable.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here